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Increased blood pressure (BP) is the single biggest contributing risk factor to the global disease burden. May
Measurement Month (MMM) is a global initiative of the International Society of Hypertension aimed at raising
awareness of high BP. In Australia, hypertension affects around six million adults and continues to remain the
greatest attributable cause of cardiovascular mortality and morbidity (48.3%), stroke deaths (28%), and kidney
disease (14%). An opportunistic cross-sectional survey was carried out during May 2017 predominantly in capital
cities across Australia which included adult volunteers. Blood pressure measurement, the definition of hyperten-
sion and statistical analysis followed the standard MMM protocol. Additional information obtained included an-
thropometric data and responses to questionnaires on demographic, lifestyle, and environmental factors. Data
were collected from 3817 individuals. After multiple imputation, of the 3758 individuals for whom a mean of
the second and third BP reading was available, 1188 (31.2%) had hypertension. Of 3213 individuals not receiving
antihypertensive treatment, 591 (18.4%) were hypertensive, and 239 (40.1%) of the 596 individuals receiving
treatment had uncontrolled BP. Adjusted BP was higher in association with antihypertensive medication, cere-
brovascular disease, smoking, and alcohol consumption. Blood pressure was higher when measured on the right
arm and on Tuesdays. MMM17 was one of the largest BP screening campaigns undertaken in Australia using stan-
dardized BP measurements. In line with previous surveys, around one-third of screened adults had hypertension
and approximately 40% of treated individuals remained uncontrolled. These results suggest that opportunistic
screening can identify significant numbers with raised BP.
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Introduction
In Australia, hypertension continues to remain the greatest
attributable cause of cardiovascular mortality and morbid-
ity (48.3%), stroke deaths (28%), and kidney disease (14%).1
Despite the availability of effective antihypertensivemedi-
cations through an efficient and affordable health care sys-
tem, the management of blood pressure (BP) remains a
national challenge. May Measurement Month 2017
(MMM17) in Australia was part of the global BP screening
campaign initiated by the International Society of
Hypertension (ISH) and endorsed by the World
Hypertension League (WHL) and the High Blood Pressure
Research Council of Australia and the National Heart
Foundation.
Methods
The Australian MMM cross-sectional survey was set up be-
tween October 2016 and April 2017, with the involvement
of most states including Western Australia, New South
Wales, Victoria, and Tasmania. One or more of the
national/state-wide leaders in the field of cardiovascular
disease and hypertension from each state were identified
and invited to participate and to co-ordinate the screening
efforts locally. The Dobney Hypertension Centre at the
University of Western Australia—Royal Perth Hospital
Campus served as the national coordinating centre. Ethics
approval was obtained centrally through the Alfred
Hospital HREC, Melbourne and further approved locally
where required. Volunteer staff training, communication
and distribution of the MMM17 protocol designed by the
Head Office of the campaign in London through the ISH, as
well as essential training materials, videos and marketing
information were developed and shared using a bespoke
MMM website. Around 25 sites were set up in a wide range
of locations across the various Australian states, including
universities, libraries, supermarkets, shopping malls, pla-
ces of worship, hospitals, and existing clinics in primary
and secondary health care facilities. Blood pressure meas-
urements, data collection, cleaning and transfer, as well as
analysis, have been described previously.2 Hypertension
was defined as a systolic BP 140mmHg or diastolic BP
90mmHg, or in those on antihypertensive medication.
Results
Data were obtained from 3817 Australian participants and
were cleaned, collated centrally, and analysed. The mean
age of the multi-cultural cohort was 41years with more
women thanmen screened in Australia and comprisingmul-
tiple ethnicities (Supplementary material online, Table
S1). Of the 3817 screened participants, 597 (15.6%) were
on antihypertensive treatment, 240 (6.3%) reported having
Type 2 diabetes, 98 (2.6%) reported a history of myocardial
infarction, and 40 (1.1%) reported a history of stroke. Two
hundred and ninety-nine (7.8%) respondents reported
smoking, 1418 (37.2%) reported alcohol consumption once
or more per week, and 29 women (1.3% of female
respondents) reported being pregnant. The mean body
mass index (BMI) of respondents was 25.76 5 kg/m2.
Of 3758 respondents with three BP readings, BP de-
creased on average by 3.2/2mmHg between the first and
third readings (Supplementary material online, Table S2).
The age-standardized and sex-standardized mean BP was
123.3/78.7mmHg in those not on treatment, and 131.5/
83.2mmHg in those on treatment.
After imputation, of the 3810 individuals for whom a
mean of the second and third reading was available, or of
those who were on antihypertensive treatment, 1188
(31.2%) participants were hypertensive. Excluding partici-
pants taking antihypertensive medication, 591 (18.4%) of
3213 participants with hypertension were not receiving
treatment. Among participants who were receiving treat-
ment for hypertension, 239 of 596 (40.1%) had uncontrolled
BP.
Based on a linear regression analysis, the association be-
tween age and sex with systolic BP in people who were not
receiving antihypertensive treatment showed a linear in-
crease, with the mean BP in female exceeding the mean BP
in men at 85–90 years of age. For diastolic BP, the relation-
ship shows an inverted U shape, with highest levels at age
50–55years in males and 40–45 in females, and with BP in
women lower than in men until aged 85–90 years
(Supplementary material online, Figure S1). After adjust-
ment for age and sex (allowing for an interaction), signifi-
cantly higher systolic and diastolic BP were apparent
in people receiving antihypertensive treatment
(Supplementary material online, Figure S2). Adjusting for
age, sex, and antihypertensive treatment, systolic and dia-
stolic BP were also significantly higher in those measured
on the right arm. Diastolic BP readings in pregnant women
and in people with a previous history of myocardial infarc-
tion were significantly lower than readings from the com-
parator groups. Increasing BMI was associated with
significant increases in both systolic and diastolic BP
(Supplementarymaterial online, Figure S3).
Discussion
In Australia, MMM17 detected 1188 adults (31.2% of those
screened) with hypertension, of which 591 (18.4%) were
untreated and 239 (40.1%) were uncontrolled. This data is
commensurate with global MMM17 and previously collated
data indicative of relatively low levels of hypertension con-
trol rates.2 Results from a National Blood Pressure
Screening day in Australia that screened around 14 000
adults on a single day revealed similar results with 34% of
the subjects tested demonstrating elevated BP.3 The rele-
vance of good BP measurement techniques is reinforced by
the data from MMM17. With standardized measurement of
three readings BP decreased significantly with each subse-
quent reading, with a marked difference in the proportion
of people with BP levels fulfilling criteria of hypertension
depending on which reading was used. The prevalence of
hypertension was lowest when derived from the mean of
the second and third reading. Further emphasis and educa-
tion on adequate BP measurement techniques seems
therefore relevant.
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The proportion of participants with hypertension (in-
cluding those on treatment) was high in Australia (31.2%)
and on par with the worldwide (34.9%) and previous na-
tional estimates.3,4 The findings of lower BP in pregnant
women, the usual patterns of systolic and diastolic BP with
age, and the association of alcohol consumption with in-
creased BP were consistent with the global MMM17 data.2
Our findings also highlight that people with treated hyper-
tension and cerebrovascular disease have less well con-
trolled BP, emphasizing the need for more assertive
treatment in such high-risk patients.
Reporting bias by participants or the inability to distin-
guish duration and degree of exposure may not clearly re-
veal the association of smoking status with increased BP.
However, smoking and alcohol consumption are also likely
to be under-reported, and the accuracy of reported intake
might differ by region and culture. Limitations of these
data include, the likelihood of a proportion of false-
positive diagnoses as in any screening taking place on a sin-
gle occasion. By design, they were not intended to be
based on representative samples of the Australian states
where screening took place. They involved predominantly
major cities, not so much rural areas, and hence true prev-
alence cannot be reported. Furthermore, although BP
readings were standardized and taken using automated
devices by trained volunteers, the environment in which
these were obtained was diverse.
Overall, MMM17 emerged as an effective campaign, car-
ried out with extensive support from volunteer staff, dona-
tions of devices to measure BP, and local support with an
estimated expenditure of around 1$per patient screened.
Even if only around half of new hypertension cases were
correctly identified, at worst, useful advice such as healthy
diet, lifestyle advice and appropriate follow-up was pro-
vided to those who had BP in the high end of the normal
range rather than truly elevated BP.
Supplementary material
Supplementary material is available at European Heart
Journal - Supplements online.
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